

Article

Not peer-reviewed version

Electrochemical Radical Tandem Difluoroethylation/Cyclization of Unsaturated Amides to Access MeCF₂-Featured Indolo/Benzoimidazo[2,1-A]isoquinolin-6(5H)-Ones

[Yunfei Tian](#)^{*}, Dongyu Guo, Luping Zheng, Shaolu Yang, Ningning Zhang, [Weijun Fu](#)^{*}, [Zejiang Li](#)^{*}

Posted Date: 15 January 2024

doi: 10.20944/preprints202401.1047.v1

Keywords: electrochemical synthesis; difluoroethylation; radical; polycyclic compounds; tandem cyclization



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Electrochemical Radical Tandem Difluoroethylation/Cyclization of Unsaturated Amides to Access MeCF₂-Featured Indolo/Benzoimidazo[2,1-*a*]isoquinolin-6(5*H*)-ones

Yunfei Tian ^{1,*}, Dongyu Guo ², Luping Zheng ¹, Shaolu Yang ¹, Ningning Zhang ¹, Weijun Fu ^{1,*} and Zejiang Li ^{2,*}

¹ College of Chemistry and Chemical Engineering, Key Laboratory of Fuction-Oriented Porous Materials of Henan Province, Luoyang Normal University, Luoyang, Henan 471934, P. R. China

² Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, State Key Laboratory of New Pharmaceutical Preparations and Excipients, College of Chemistry & Materials Science, and Key Laboratory of Chemical Biology of Hebei Province, Hebei University, Baoding, Hebei 071002, P. R. China

* Correspondence: tianyunfly1120@163.com; wjfu@lynu.edu.cn; lizejiang898@126.com

Abstract: A metal-free electrochemical oxidative difluoroethylation of 2-arylbenzimidazoles was accomplished, which provided an efficient strategy for the synthesis of MeCF₂-containing benzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-ones. In addition, the method also enabled the efficient construction of various difluoroethylated indolo[2,1-*a*]isoquinolin-6(5*H*) ones. Notably, this electrochemical synthesis protocol proceeded well under mild conditions without metal catalysts or exogenous additives/oxidants added.

Keywords: electrochemical synthesis; difluoroethylation; radical; polycyclic compounds; tandem cyclization


1. Introduction

Organofluorine compounds are very useful and attractive organic molecules, which play pivotal roles in pharmaceuticals, agrochemicals, and performance materials [1-6]. Among various fluorine-containing groups, the difluoroethyl group (CF₂Me) is receiving more and more attention due to its special chemical and biological properties [7-9]. In particular, the introduction of a difluoroethyl group can improve the metabolic stability and potency of a target molecule [10,11]. Therefore, it is highly demanded to develop new and efficient protocols for the rapid introduction of difluoroethyl group to target compounds. In this context, the radical strategy has emerged as a powerful approach for the synthesis of CF₂Me-containing compounds. However, recent developments in this direction have always involved peroxides or photoredox catalysts [12-16]. On the other hand, electrochemical synthesis has also attracted much attention due to the advantages of avoiding the usage of chemical oxidants and reductants [17-23]. Very recently, much progress in electrochemical difluoroethylation has been made by Hu [24] and our group [25,26]. Although these methods have provided innovative transformations, the preparation of CF₂Me-substituted polycyclic compounds has not been achieved.


Benzo[4,5]imidazo[2,1-*a*]isoquinolines and indolo [2,1-*a*]isoquinolines, which are significant classes of fused polycyclic nitrogen-containing scaffolds and widely exist in natural products and pharmaceuticals (Scheme 1-1) [27-31]. Although substantial efforts have been contributed to the construction of these polycyclic compounds [32-37], the CF₂Me-containing target polycycles remain a great challenge to date (Scheme 1-2). As part of our continuing interest in difluoroethylation functionalizations, we anticipated that the radical cyclization process would provide a feasible platform for the synthesis of CF₂Me-revised target polycycles. Herein, we report an electrochemical-induced radical cascade cyclization strategy, whereby a series of CF₂Me-substituted indolo [2,1-

a]isoquinolines and benzo[4,5]imidazo[2,1-*a*]isoquinolines could be efficiently prepared under mild and chemical oxidants-free conditions (Scheme 1-3).

1. Biologically important benzimidazole- or indolo-fused isoquinoline derivatives



2. Previous work: radical difluoroethylation for difluoroethylated heterocycles



3. **This work:** the electrochemical-promoted difluoroethylated polycycles construction




Figure 1. Strategies for radical difluoroethylated heterocycles.

2. Results and Discussion

We began our investigation by examining the electrochemical difluoroethylation reaction of *N*-methacryloyl-2-phenylbenzimidazole (**1a**) with NaSO₂CF₂Me (**2a**) (Table 1). To our delight, the electrolysis furnished the 86% yield of the desired cyclization product **3a** with a constant voltage of 2.1 V in an undivided cell equipped with a carbon plate anode and a Pt plate cathode (Table 1, entry 1). Then the various conditions, such as voltage, electrode material, electrolyte, and solvent were measured. Neither lower voltage nor higher voltage led to higher efficiency (entry 2-3). C(+) | Pt(−) was proved to be the optimal electrode material combination compared to others (entry 4-6). A switch of electrolytes LiClO₄ to other electrolytes such as Et₄NClO₄, ⁿBu₄NClO₄, or ⁿBu₄NPF₆ significantly restrained the reaction (entry 7-9). The change of solvent proportion failed to improve the yield of **3a** (entries 10–11). The cyclization product **3a** could not be observed without electricity (entry 12).

Table 1. Optimization of the typical conditions^a.


Entry	variations from standard conditions	Yield (%) ^b
1	none	86

2	1.8 V	52
3	2.5 V	65
4	C (+) Ni (-)	62
5	C (+) C (-)	56
6	Pt (+) Pt (-)	39
7	ⁿ Bu ₄ NClO ₄ as the electrolyte	37
8	Et ₄ NClO ₄ as the electrolyte	61
9	ⁿ Bu ₄ NPF ₆ as the electrolyte	26
10	CH ₃ CN/H ₂ O (9:1)	47
11	CH ₃ CN/H ₂ O (1:1)	66
12	No electricity	n.d

^aReaction conditions: Carbon plate (10 mm * 10 mm * 3 mm) as the anode, platinum plate (10 mm * 10 mm * 0.20 mm) as the cathode, undivided cell, 2.1 V, **1a** (0.2 mmol), **2a** (0.6 mmol), LiClO₄ (0.3 M), CH₃CN (4.5 mL), H₂O (1.5 mL), rt, 3 h. ^bIsolated yields.


With the above-optimized conditions in hand, we investigated the substrate scopes (Scheme 1). It can be seen that a wide range of 2-arylbenzimidazoles with either electron-donating or electron-withdrawing substituents worked well and afforded the corresponding products in good to high yields (**3a-3h**). The ortho-substituted 2-arylbenzimidazoles were also tolerated with the reaction, and the desired products were obtained in 70-88% yields (**3i-3m**). When utilizing meta-substituted 2-arylbenzimidazoles as the starting materials, the reactions demonstrated good site-selectivity with no regioisomers detected (**3n**). It also occurred smoothly on disubstituted substrates to produce the cyclization products in good yields (**3o** and **3p**). The 3, 5-di substituent was successfully converted to the target product **3q** in 72% yield without the interference of steric hindrance. For Ar1 substituents, the dimethyl-substituted *N*-methacryloyl-2-phenylbenzimidazoles gave the desired products **3r** in good yields. The substrates with phenyl or benzyl substitution of the terminal olefin were also able to produce the relevant products (**3s** and **3t**). The substrates containing naphthalene or thiophene were all compatible with this reaction mode, delivering the corresponding products **3u** and **3v** in 74% and 67% yields, respectively.

Subsequently, we turned our attention to the synthesis of indolo[2,1-*a*]isoquinoline derivatives, which are key structural skeletons of various pharmaceuticals. As shown in Scheme 2, the desired CF₂Me-substituted indolo[2,1-*a*]isoquinoline derivatives were obtained in moderate to excellent yields. The halosubstituted (F-, Cl-, Br-) substrates also smoothly underwent a cyclization process to give the corresponding products with good efficiency (**5b-5e**). Moreover, the substrates with ethyl group at the C3 position of the indole ring were demonstrated to be suitable substrates to provide the final products in 65-75% yield (**5f-5h**). Notably, this method was also enable to access cyclopropyldifluoromethylated indolo[2,1-*a*]isoquinoline (**5i**).




Scheme 1. Scope of the substrates 2-arylbenzimidazoles. Reaction conditions: Carbon plate (10 mm * 10 mm * 3 mm) as the anode, platinum plate (10 mm * 10 mm * 0.20 mm) as the cathode, undivided cell, 2.1 V, **1** (0.2 mmol), **2a** (0.6 mmol), LiClO_4 (0.3 M), CH_3CN (4.5 mL), H_2O (1.5 mL), rt, 3 h, isolated yields.

Then some control experiments were carried out to investigate the mechanism of this reaction (Scheme 3). When radical scavenger 2,6-di-tert-butyl-4-methylphenol (BHT) was added to the standard reaction system, the reaction was significantly suppressed, and the desired product was not detected by TLC. When adding the 1,1-diphenylethylene into the system, only the 16% yield of the target product was obtained and the radical adduct was found by HRMS. The two experiments suggested that the reaction may involve a radical pathway. To further understand the details of this reaction mechanism, cyclic voltammetry (CV) experiments were performed. As shown in Figure 2, the oxidation peaks of **1a** and **2a** were at 1.47 V and 0.67 V, respectively. These results indicated that **2a** was more easily oxidized than **1a**.



Scheme 2. Scope of the substrates 2-arylimides. Reaction conditions: Carbon plate (10 mm * 10 mm * 3 mm) as the anode, platinum plate (10 mm * 10 mm * 0.20 mm) as the cathode, undivided cell, 2.1 V, **4** (0.2 mmol), **2** (0.6 mmol), LiClO_4 (0.3 M), CH_3CN (4.5 mL), H_2O (1.5 mL), rt, 3 h, isolated yields.



Scheme 3. Reactions for mechanistic determination.





Figure 2. Cyclic voltammograms of substrates in 0.1 M $\text{LiClO}_4/(\text{CH}_3\text{CN}/\text{H}_2\text{O})$, using glassy carbon working electrode, platinum wire counter electrode, and Ag/AgNO_3 reference electrode at 50 mVs^{-1} scan rates: (a) Background, (b) **1a** (5 mM), (c) **2a** (5 mM), (d) **1a** (5 mM) and **2a** (5 mM).

Based on the above results, a plausible mechanism of this reaction was proposed (Scheme 4). First, anodic oxidation of $\text{MeCF}_2\text{SO}_2\text{Na}$ generated the $\text{MeCF}_2\text{SO}_2^\bullet$ radical, which then liberated SO_2 to afford MeCF_2^\bullet radical. Subsequently, the addition of MeCF_2^\bullet radical to the double bond of **1a** yielded a carbon-centred radical **A**. The intermediate **A** underwent further intramolecular radical cyclization to afford the aryl radical **B**. The intermediate **B** was oxidized at the anode to give aryl cation **C**, which resulted in the expected product **3a** via a deprotonation process.



Scheme 4. Proposed reaction mechanism.

3. Materials and Methods

3.1. General Methods

^1H and ^{13}C NMR and ^{19}F NMR spectra were recorded on a Bruker advance III 400 or 500 spectrometer in CDCl_3 with TMS as the internal standard. High-resolution mass spectral analysis (HRMS (TOF)) data were measured on a Bruker Apex II. All products were identified by ^1H , ^{19}F , ^{13}C NMR and HRMS. The starting materials were purchased from Energy, J&K Chemicals, or Aldrich and used without further purification. The conversion was monitored by thin-layer chromatography (TLC). Flash column chromatography was performed over silica gel (200-300 mesh). Cyclic voltammetry experiments were carried out in an electrochemical workstation (CHI660E, Shanghai, China). 2-arylbenzimidazoles/2-arylindoles were prepared according to reported procedures.³⁵

3.2. General Procedure for the Reaction

To a 20 mL test tube with a stir bar was charged with, 2-arylbenzimidazoles/2-arylindoles (1 equiv., 0.2 mmol), $\text{MeCF}_2\text{SO}_2\text{Na}$, or sodium cyclopropyldifluoromethylsulfinate (3 equiv., 0.6 mmol), LiClO_4 (0.3 M), MeCN (4.5 mL), H_2O (1.5 mL). The tube was equipped with a carbon plate (10 mm × 10 mm × 3 mm) as the anode and a platinum plate (10 mm × 10 mm × 0.2 mm) as the cathode. The reaction mixture was electrolyzed in an undivided cell at room temperature under a constant voltage of 2.1 V for 3 h. Upon completion, the mixture was extracted with EtOAc (10 mL × 3). The combined organic phases were dried over Na_2SO_4 and condensed under vacuum. The residue was purified by silica gel column chromatography to afford the final products. (^1H NMR, ^{19}F NMR and ^{13}C NMR of compounds (**3a–v** and **5a–i**) are shown in Supplementary Materials).

5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3a). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 56.1 mg, 86 % yield. ^1H NMR (400 MHz, CDCl_3): δ 8.52 – 8.49 (m, 1H), 8.37 – 8.35 (m, 1H), 7.84 – 7.82 (m, 1H), 7.59

– 7.55 (m, 1H), 7.50 (t, $J = 7.2$ Hz, 2H), 7.47 – 7.40 (m, 2H), 3.30 – 3.18 (m, 1H), 2.79 – 2.67 (m, 1H), 1.72 (s, 3H), 1.34 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 172.2, 149.6, 144.0, 140.0, 131.5, 131.3, 127.9, 126.8, 126.0, 125.9, 125.6, 122.6 (t, $J = 240.5$ Hz), 122.3, 119.8, 115.7, 48.2 (t, $J = 23.9$ Hz), 45.5, 31.1, 24.7 (t, $J = 27.3$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -86.07 – -86.30 (m, 2F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{19}\text{H}_{16}\text{F}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 327.1303; Found 327.1306.

5-(2,2-difluoropropyl)-3,5-dimethylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5H)-one (**3b**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 55.7 mg, 82 % yield. ^1H NMR (500 MHz, CDCl_3): δ 8.37 (d, $J = 8.0$ Hz, 1H), 8.35 – 8.33 (m, 1H), 7.80 – 7.79 (m, 1H), 7.44 – 7.38 (m, 2H), 7.30 (d, $J = 8.5$ Hz, 1H), 7.26 (s, 1H), 3.21 (q, $J = 15.0$ Hz, 1H), 2.70 (q, $J = 15.5$ Hz, 1H), 2.45 (s, 3H), 1.70 (s, 3H), 1.32 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.3, 149.8, 144.1, 141.8, 140.1, 131.4, 129.0, 127.1, 126.0, 125.8, 125.3, 122.5 (t, $J = 240.6$ Hz), 119.7, 119.6, 115.6, 48.2 (t, $J = 24.1$ Hz), 45.5, 31.0, 24.7 (t, $J = 27.4$ Hz), 21.8. ^{19}F NMR (471 MHz, CDCl_3): δ -86.01 – -86.20 (m, 2F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{20}\text{H}_{18}\text{F}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 341.1460; Found 341.1461.

5-(2,2-difluoropropyl)-3-fluoro-5-methylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5H)-one (**3c**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 58.5 mg, 85 % yield. ^1H NMR (400 MHz, CDCl_3): δ 8.50 (dd, $J = 8.4, 6.0$ Hz, 1H), 8.34 (d, $J = 7.6$ Hz, 1H), 7.80 (d, $J = 7.6$ Hz, 1H), 7.46 – 7.39 (m, 2H), 7.22 – 7.15 (m, 2H), 3.29 – 3.17 (m, 1H), 2.71 – 2.59 (m, 1H), 1.70 (s, 3H), 1.40 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.6, 164.6 (d, $J = 252.5$ Hz), 148.8, 144.0, 142.9 (d, $J = 7.9$ Hz), 131.4, 128.5 (d, $J = 9.1$ Hz), 125.7 (d, $J = 37.5$ Hz), 122.4 (t, $J = 240.6$ Hz), 119.7, 118.9, 115.9 (d, $J = 22.4$ Hz), 115.6, 113.7 (d, $J = 23.2$ Hz), 48.3 (t, $J = 23.7$ Hz), 45.7, 30.9, 24.7 (t, $J = 27.3$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -85.51 – -86.22 (m, 1F), -87.32 – -88.02 (m, 1F), -106.94 – -106.99 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{19}\text{H}_{15}\text{F}_3\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 345.1209; Found 345.1211.

3-chloro-5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5H)-one (**3d**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 62.6 mg, 87 % yield. ^1H NMR (400 MHz, CDCl_3): δ 8.43 (d, $J = 8.4$ Hz, 1H), 8.34 (d, $J = 6.8$ Hz, 1H), 7.81 (d, $J = 8.0$ Hz, 1H), 7.47 – 7.42 (m, 4H), 3.28 – 3.16 (m, 1H), 2.73 – 2.61 (m, 1H), 1.71 (s, 3H), 1.40 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.5, 148.7, 143.9, 141.8, 137.5, 131.4, 128.5, 127.4, 127.0, 126.0, 125.8, 122.5 (t, $J = 239.0$ Hz), 120.9, 119.8, 115.6, 48.2, 45.5 (d, $J = 3.3$ Hz), 30.9, 24.8 (t, $J = 27.2$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -85.56 – -86.27 (m, 1F), -87.33 – -88.03 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{19}\text{H}_{15}\text{ClF}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 361.0914; Found 361.0915.

3-bromo-5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5H)-one (**3e**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 64.0 mg, 79 % yield. ^1H NMR (500 MHz, CDCl_3): δ 8.37 – 8.33 (m, 2H), 7.82 – 7.80 (m, 1H), 7.63 – 7.61 (m, 2H), 7.46 – 7.41 (m, 2H), 3.27 – 3.17 (m, 1H), 2.72 – 2.63 (m, 1H), 1.71 (s, 3H), 1.41 (t, $J = 18.5$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.4, 148.7, 143.9, 141.9, 131.4 (d, $J = 7.8$ Hz), 129.9, 127.5, 126.0, 125.8, 122.5 (t, $J = 238.5$ Hz), 121.4, 119.9, 115.6, 48.2 (t, $J = 23.7$ Hz), 45.5 (d, $J = 3.3$ Hz), 30.8, 24.8 (t, $J = 27.2$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -85.57 – -86.28 (m, 1F), -87.26 – -87.96 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{19}\text{H}_{15}\text{BrF}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 405.0408; Found 405.0409.

5-(2,2-difluoropropyl)-5-methyl-3-(trifluoromethyl)benzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5H)-one (**3f**). A light yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 63.0 mg, 80 % yield. ^1H NMR (500 MHz, CDCl_3): δ 8.63 (d, $J = 8.0$ Hz, 1H), 8.38 – 8.36 (m, 1H), 7.86 – 7.85 (m, 1H), 7.75 – 7.72 (m, 2H), 7.49 – 7.45 (m, 2H), 3.33 – 3.24 (m, 1H), 2.80 – 2.71 (m, 1H), 1.75 (s, 3H), 1.43 (t, $J = 18.5$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.4, 148.1, 143.9, 140.7, 132.8 (q, $J = 32.8$ Hz), 131.5, 126.7, 126.24, 126.20, 125.6, 124.7 (q, $J = 3.6$ Hz), 124.0 – 123.9 (m), 122.5 (q, $J = 271.1$ Hz), 122.5 (t, $J = 240.1$ Hz), 120.2, 115.8, 48.1 (t, $J = 23.5$ Hz), 45.7 (d, $J = 3.3$ Hz), 30.8, 24.8 (t, $J = 27.2$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -62.91 (s, 3F), -85.44 – -86.13 (m, 1F), -87.85 – -88.51 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{20}\text{H}_{15}\text{F}_5\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 395.1177; Found 395.1179.

5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline-3-carboxylate (**3g**). A light yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 7/1), 57.6 mg, 75 % yield. ^1H NMR (400 MHz, CDCl_3): δ 8.57 (d, $J = 8.0$ Hz, 1H), 8.38 – 8.36 (m, 1H), 8.18 (s, 1H), 8.13 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.86 – 7.84 (m, 1H), 7.49 – 7.44 (m, 2H), 3.98 (s, 3H), 3.31 – 3.19 (m, 1H), 2.87 – 2.75 (m, 1H), 1.76 (s, 3H), 1.40 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR

(125 MHz, CDCl₃): δ 171.7, 166.1, 148.6, 144.1, 140.3, 132.4, 131.5, 128.7, 128.3, 126.18, 126.16, 126.14, 126.12, 122.6 (t, J = 238.6 Hz), 120.1, 115.8, 52.5, 48.3 (t, J = 23.5 Hz), 45.7 (d, J = 3.4 Hz), 30.8, 24.8 (t, J = 27.2 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -85.83 – -86.54 (m, 1F), -87.26 – -87.96 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for C₂₁H₁₈F₂N₂O₃ (M+H)⁺ 385.1358; Found 385.1360.

5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline-3-carbonitrile (3h). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 7/1), 43.5 mg, 62% yield. ¹H NMR (500 MHz, CDCl₃): δ 8.59 (d, J = 8.0 Hz, 1H), 8.36 – 8.34 (m, 1H), 7.86 – 7.84 (m, 1H), 7.78 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.48 – 7.46 (m, 2H), 3.31 – 3.21 (m, 1H), 2.76 – 2.66 (m, 1H), 1.73 (s, 3H), 1.46 (t, J = 19.0 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 170.9, 147.6, 143.9, 141.0, 131.4, 131.0, 130.9, 126.7, 126.5, 126.3, 122.5 (t, J = 238.6 Hz), 120.3, 118.0, 115.8, 114.5, 48.1 (t, J = 23.3 Hz), 45.5 (d, J = 3.1 Hz), 30.6, 29.6, 24.8 (t, J = 27.1 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -85.22 – -85.93 (m, 1F), -88.52 – -89.22 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for C₂₀H₁₅F₂N₃O (M+H)⁺ 352.1256; Found 352.1260.

5-(2,2-difluoropropyl)-1,5-dimethylbenzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3i). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 55.1 mg, 81% yield. ¹H NMR (400 MHz, CDCl₃): δ 8.38 (d, J = 8.0 Hz, 1H), 8.36 – 7.34 (m, 1H), 7.81 – 7.79 (m, 1H), 7.45 – 7.38 (m, 2H), 7.31 (d, J = 8.0 Hz, 1H), 7.27 (s, 1H), 3.22 (q, J = 15.2 Hz, 1H), 2.72 (q, J = 15.2 Hz, 1H), 2.47 (s, 3H), 1.71 (s, 3H), 1.34 (t, J = 18.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 172.3, 149.8, 144.0, 141.8, 140.0, 131.4, 129.1, 127.2, 125.9, 125.8, 125.3, 122.6 (t, J = 240.6 Hz), 119.7, 119.6, 115.6, 48.2 (t, J = 23.9 Hz), 45.5, 31.1, 24.7 (t, J = 27.3 Hz), 21.9. ¹⁹F NMR (471 MHz, CDCl₃): δ -85.99 – -86.18 (m, 2F). HRMS (ESI-TOF) m/z : Calcd for C₂₀H₁₈F₂N₂O (M+H)⁺ 341.1460; Found 341.1462.

5-(2,2-difluoropropyl)-1-methoxy-5-methylbenzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3j). A brown solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 49.8 mg, 70% yield. ¹H NMR (500 MHz, CDCl₃): δ 8.39 – 8.37 (m, 1H), 7.91 – 7.89 (m, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.43 – 7.39 (m, 2H), 7.12 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 4.14 (s, 3H), 3.23 (q, J = 15.0 Hz, 1H), 2.71 (q, J = 15.5 Hz, 1H), 1.72 (s, 3H), 1.32 (t, J = 18.5 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 172.1, 158.7, 147.7, 144.3, 142.6, 131.7, 130.3, 125.6, 124.8 (t, J = 463.0 Hz), 122.5, 120.5, 119.1, 115.5, 111.8, 110.4, 56.6, 48.6 (t, J = 23.9 Hz), 45.4, 31.5, 24.7 (t, J = 27.4 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -85.88 – -86.06 (m, 2F). HRMS (ESI-TOF) m/z : Calcd for C₂₀H₁₈F₂N₂O₂ (M+H)⁺ 357.1409; Found 357.1410.

5-(2,2-difluoropropyl)-1-fluoro-5-methylbenzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3k). A yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 55.0 mg, 80% yield. ¹H NMR (500 MHz, CDCl₃): δ 8.38 – 8.37 (m, 1H), 7.94 – 7.92 (m, 1H), 7.51 (td, J = 8.0, 5.0 Hz, 1H), 7.47 – 7.43 (m, 2H), 7.31 (d, J = 8.0 Hz, 1H), 7.24 – 7.21 (m, 1H), 3.29 – 3.19 (m, 1H), 2.76 – 2.67 (m, 1H), 1.72 (s, 3H), 1.39 (t, J = 19.0 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.6, 160.4 (d, J = 262.1 Hz), 145.8 (d, J = 8.4 Hz), 144.2, 142.5, 131.8 (d, J = 9.6 Hz), 130.4, 126.0 (d, J = 14.0 Hz), 122.8, 122.5 (t, J = 240.6 Hz), 120.5, 115.8, 115.6, 115.5, 111.8 (d, J = 9.9 Hz), 48.5 (t, J = 23.7 Hz), 45.4, 31.3, 24.8 (t, J = 27.3 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -85.44 – -86.11 (m, 1F), -87.00 – -87.69 (m, 1F), -107.12 – -107.16 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for C₁₉H₁₅F₃N₂O (M+H)⁺ 345.1209; Found 345.1211.

1-chloro-5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3l). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 63.4 mg, 88% yield. ¹H NMR (400 MHz, CDCl₃): δ 8.39 (dd, J = 6.0, 3.2 Hz, 1H), 7.93 (dd, J = 6.0, 3.2 Hz, 1H), 7.58 – 7.56 (m, 1H), 7.47 – 7.42 (m, 4H), 3.30 – 3.19 (m, 1H), 2.77 – 2.65 (m, 1H), 1.72 (s, 3H), 1.38 (t, J = 18.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.4, 147.0, 143.9, 142.9, 133.5, 131.5, 130.6, 130.4, 126.3, 125.9, 125.7, 122.5 (t, J = 238.8 Hz), 120.7, 120.5, 115.7, 48.49 (t, J = 23.7 Hz), 45.76 (d, J = 3.5 Hz), 31.43 (s), 24.80 (t, J = 27.3 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -85.21 – -85.92 (m, 1F), -86.99 – -87.70 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for C₁₉H₁₅ClF₂N₂O (M+H)⁺ 361.0914; Found 361.0916.

1-bromo-5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3m). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 63.2 mg, 78% yield. ¹H NMR (500 MHz, CDCl₃): δ 8.38 (dd, J = 6.0, 3.0 Hz, 1H), 7.93 (dd, J = 6.0, 3.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.49 – 7.44 (m, 3H), 7.33 (t, J = 8.0 Hz, 1H), 3.29 – 3.20 (m, 1H), 2.76 – 2.67 (m, 1H), 1.72 (s, 3H), 1.38 (t, J = 19.0 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.3, 147.1, 143.5,

143.1, 135.3, 130.8, 130.6, 126.4, 126.3, 125.9, 122.5 (t, $J = 240.7$ Hz), 121.8, 121.3, 120.8, 115.7, 48.4 (t, $J = 23.5$ Hz), 45.9 (d, $J = 3.2$ Hz), 31.5, 24.8 (t, $J = 27.3$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -85.15 – -85.86 (m, 1F), -86.99 – -87.69 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{19}\text{H}_{15}\text{BrF}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 405.0408; Found 405.0412.

5-(2,2-difluoropropyl)-2,5-dimethylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-one (**3n**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 51.7 mg, 76% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.37 – 8.35 (m, 1H), 8.32 (s, 1H), 7.83 – 7.81 (m, 1H), 7.45 – 7.40 (m, 2H), 7.37 (s, 2H), 3.22 (q, $J = 15.5$ Hz, 1H), 2.70 (q, $J = 15.5$ Hz, 1H), 2.46 (s, 3H), 1.69 (s, 3H), 1.33 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 172.4, 149.8, 143.9, 137.9, 137.2, 132.4, 131.5, 126.7, 126.1, 125.8, 125.5, 122.6 (t, $J = 240.5$ Hz), 122.0, 119.7, 115.6, 48.2 (t, $J = 24.0$ Hz), 45.3 (d, $J = 2.2$ Hz), 31.1, 24.7 (t, $J = 27.3$ Hz), 20.9. ^{19}F NMR (471 MHz, CDCl_3): δ -86.02 – -86.20 (m, 2F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{20}\text{H}_{18}\text{F}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 341.1460; Found 341.1462.

5-(2,2-difluoropropyl)-1,3,5-trimethylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-one (**3o**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 58.0 mg, 82% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.39 – 8.38 (m, 1H), 7.83 – 7.81 (m, 1H), 7.44 – 7.39 (m, 2H), 7.15 (s, 2H), 3.27 – 3.18 (m, 1H), 3.02 (s, 3H), 2.76 – 2.67 (m, 1H), 2.42 (s, 3H), 1.71 (s, 3H), 1.32 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 172.5, 150.0, 144.2, 141.1, 140.2, 139.7, 132.3, 130.6, 125.5, 125.4, 125.3, 122.7 (t, $J = 240.6$ Hz), 119.9, 118.4, 115.6, 48.5 (t, $J = 24.1$ Hz), 45.4, 31.7, 24.7 (t, $J = 27.3$ Hz), 24.6, 21.6. ^{19}F NMR (471 MHz, CDCl_3): δ -85.66 – -85.96 (m, 2F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{21}\text{H}_{20}\text{F}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 355.1616; Found 355.1619.

1,3-dichloro-5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-one (**3p**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 58.5 mg, 74% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.38 – 8.36 (m, 1H), 7.92 – 7.91 (m, 1H), 7.58 (d, $J = 2.0$ Hz, 1H), 7.48 – 7.44 (m, 2H), 7.40 (d, $J = 1.5$ Hz, 1H), 3.29 – 3.20 (m, 1H), 2.72 – 2.63 (m, 1H), 1.73 (s, 3H), 1.45 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 170.7, 146.3, 144.1, 143.8, 136.2, 134.4, 131.3, 130.5, 126.5, 126.1, 122.4 (t, $J = 240.8$ Hz), 120.8, 119.2, 115.6, 48.4 (t, $J = 23.4$ Hz), 45.8 (d, $J = 3.0$ Hz), 31.3, 24.9 (t, $J = 27.1$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -85.15 – -85.86 (m, 1F), -87.94 – -88.64 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{19}\text{H}_{14}\text{Cl}_2\text{F}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 395.0524; Found 395.0527.

5-(2,2-difluoropropyl)-2,4,5-trimethylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-one (**3q**). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 51.0 mg, 72% yield. ^1H NMR (400 MHz, CDCl_3): δ 8.35 – 8.33 (m, 2H), 7.81 (dd, $J = 7.0, 1.6$ Hz, 1H), 7.42 (pd, $J = 7.2, 1.6$ Hz, 2H), 7.18 (s, 1H), 3.34 – 3.11 (m, 2H), 2.62 (s, 3H), 2.41 (s, 3H), 1.80 (s, 3H), 1.38 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 173.5, 150.4, 144.1, 137.7, 137.5, 136.4, 134.6, 131.5, 125.9, 125.2, 122.9 (t, $J = 240.3$ Hz), 122.9, 119.6, 115.7, 46.6, 44.9 (t, $J = 23.5$ Hz), 27.2, 24.5 (t, $J = 27.5$ Hz), 22.8, 20.6. ^{19}F NMR (471 MHz, CDCl_3): δ -88.43 – -88.61 (m, 1F), -88.66 – -88.85 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{21}\text{H}_{20}\text{F}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 355.1616; Found 355.1619.

3-bromo-5-(2,2-difluoropropyl)-5,9,10-trimethylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-one (**3r**). A yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 72.7 mg, 84% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.31 (d, $J = 9.0$ Hz, 1H), 8.12 (s, 1H), 7.60 – 7.58 (m, 2H), 7.56 (s, 1H), 3.26 – 3.16 (m, 1H), 2.70 – 2.61 (m, 1H), 2.41 (s, 3H), 2.39 (s, 3H), 1.70 (s, 3H), 1.39 (t, $J = 18.5$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.3, 148.0, 142.4, 141.7, 135.2, 135.0, 131.2, 129.9, 129.7, 127.2, 125.3, 122.4 (t, $J = 240.7$ Hz), 121.7, 120.0, 115.9, 48.2 (t, $J = 23.8$ Hz), 45.4 (d, $J = 3.3$ Hz), 30.8, 24.7 (t, $J = 27.2$ Hz), 20.5, 20.4. ^{19}F NMR (471 MHz, CDCl_3): δ -85.57 – -86.28 (m, 1F), -87.17 – -87.87 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{21}\text{H}_{19}\text{BrF}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}$) $^+$ 433.0721; Found 433.0723.

5-(2,2-difluoropropyl)-5-phenylbenzo[4,5]imidazo[2,1-*a*]isoquinolin-6(5*H*)-one (**3s**). A yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 44.2 mg, 57% yield. ^1H NMR (400 MHz, CDCl_3): δ 8.58 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.26 (d, $J = 7.6$ Hz, 1H), 7.84 (d, $J = 7.6$ Hz, 1H), 7.56 – 7.37 (m, 4H), 7.32 – 7.24 (m, 4H), 7.22 – 7.17 (m, 3H), 3.98 – 3.07 (m, 1H), 3.18 – 3.07 (m, 1H), 1.47 (t, $J = 18.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 170.3, 149.7, 144.1, 142.3, 139.8, 131.6, 131.2, 129.3, 129.1, 128.2, 128.1, 126.8, 125.93, 125.87, 125.7, 123.6, 122.8 (t, $J = 239.8$ Hz), 119.9, 115.7, 53.4, 46.0 (t, $J = 23.5$ Hz), 25.3 (t, $J = 27.5$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -84.84 – -85.02 (m,

1F), -85.04 – -85.22 (m, 1F). HRMS (ESI-TOF) *m/z*: Calcd for C₂₄H₁₈F₂N₂O (M+H)⁺ 389.1460; Found 389.1463.

5-benzyl-5-(2,2-difluoropropyl)benzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one (3t). A white solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 52.3 mg, 65% yield. ¹H NMR (500 MHz, CDCl₃): δ 8.36 – 8.34 (m, 1H), 8.29 (d, *J* = 8.0 Hz, 1H), 7.68 – 7.66 (m, 1H), 7.63 – 7.62 (m, 2H), 7.49 – 7.46 (m, 1H), 7.41 – 7.36 (m, 2H), 6.87 (t, *J* = 7.5 Hz, 1H), 6.77 (t, *J* = 7.5 Hz, 2H), 6.49 (d, *J* = 7.5 Hz, 2H), 3.53 (d, *J* = 12.5 Hz, 1H), 3.49 – 3.41 (m, 1H), 3.17 (d, *J* = 12.5 Hz, 1H), 2.99 – 2.90 (m, 1H), 1.43 (t, *J* = 19.0 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.2, 149.2, 143.6, 137.4, 133.2, 130.9, 130.8, 129.1, 128.0, 127.8, 127.3, 125.72, 125.69, 125.4, 124.1, 122.6 (t, *J* = 240.8 Hz), 119.6, 115.4, 51.9, 50.7, 46.5 (t, *J* = 23.8 Hz), 25.1 (t, *J* = 27.3 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -83.32 – -84.00 (m, 1F), -84.83 – -85.51 (m, 1F). HRMS (ESI-TOF) *m/z*: C₂₅H₂₀F₂N₂O (M+H)⁺ 403.1616; Found 403.1617.

7-(2,2-difluoropropyl)-7-methylbenzo[h]benzo[4,5]imidazo[2,1-a]isoquinolin-8(7H)-one (3u). A yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 55.6 mg, 74% yield. ¹H NMR (500 MHz, CDCl₃): δ 10.56 (d, *J* = 8.5 Hz, 1H), 8.47 – 8.45 (m, 1H), 8.01 (d, *J* = 8.5 Hz, 1H), 7.96 – 7.94 (m, 1H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.84 – 7.81 (m, 1H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.56 (d, *J* = 8.5 Hz, 1H), 7.50 – 7.46 (m, 2H), 3.37 – 3.27 (m, 1H), 2.90 – 2.81 (m, 1H), 1.78 (s, 3H), 1.33 (t, *J* = 19.0 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 172.3, 149.7, 144.0, 140.6, 132.7, 132.0, 130.4, 130.3, 128.7, 128.4, 128.2, 126.9, 125.9, 125.8, 122.5 (d, *J* = 240.5 Hz), 123.7, 120.1, 117.6, 115.7, 47.9 (t, *J* = 24.1 Hz), 45.9, 31.0, 24.6 (t, *J* = 27.3 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -86.07 – -86.30 (m, 1F), -86.32 – -86.46 (m, 1F). HRMS (ESI-TOF) *m/z*: Calcd for C₂₃H₁₈F₂N₂O (M+H)⁺ 377.1460; Found 377.1462.

4-(2,2-difluoropropyl)-4-methylbenzo[4,5]imidazo[1,2-a]thieno[2,3-c]pyridin-5(4H)-one (3v). A yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 10/1), 44.5 mg, 67% yield. ¹H NMR (400 MHz, CDCl₃): δ 8.33 – 8.30 (m, 1H), 7.78 – 7.75 (m, 1H), 7.59 (d, *J* = 4.8 Hz, 1H), 7.44 – 7.38 (m, 2H), 7.11 (d, *J* = 5.2 Hz, 1H), 3.24 – 3.12 (m, 1H), 2.66 – 2.54 (m, 1H), 1.67 (s, 3H), 1.38 (t, *J* = 18.8 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.6, 146.4, 145.9, 143.9, 130.9, 130.4, 125.9, 125.8, 125.5, 123.6, 122.4 (t, *J* = 240.5 Hz), 119.7, 115.2, 48.2 (t, *J* = 24.3 Hz), 45.6 – 45.5 (m), 29.9, 24.5 (t, *J* = 27.3 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -86.86 – -87.18 (m, 2F). HRMS (ESI-TOF) *m/z*: Calcd for C₁₇H₁₄F₂N₂OS (M+H)⁺ 333.0868; Found 333.0870.

5-(2,2-difluoropropyl)-3,5,12-trimethylindolo[2,1-a]isoquinolin-6(5H)-one (5a). A white gummy after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 46.6 mg, 66% yield. ¹H NMR (400 MHz, CDCl₃): δ 8.62 (d, *J* = 7.2 Hz, 1H), 7.95 (d, *J* = 8.0 Hz, 1H), 7.60 – 7.58 (m, 1H), 7.41 – 7.34 (m, 3H), 7.23 (d, *J* = 8.4 Hz, 1H), 3.28 – 3.16 (m, 1H), 2.71 – 2.60 (m, 1H), 2.65 (s, 3H), 2.44 (s, 3H), 1.69 (s, 3H), 1.31 (t, *J* = 18.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 172.0, 137.3, 137.0, 134.0 (d, *J* = 30.9 Hz), 132.6, 129.7, 129.4, 128.3, 127.4, 125.2 (d, *J* = 48.0 Hz), 124.2, 123.2, 122.9 (t, *J* = 240.2 Hz), 118.2, 116.7, 113.6, 48.1 (t, *J* = 24.2 Hz), 45.0 – 44.8 (m), 31.4, 24.5 (t, *J* = 27.4 Hz), 21.5, 11.5. ¹⁹F NMR (471 MHz, CDCl₃): δ -84.11 – -84.82 (m, 1F), -85.19 – -85.89 (m, 1F). HRMS (ESI-TOF) *m/z*: Calcd for C₂₂H₂₁F₂NO (M+H)⁺ 354.1664; Found 354.1666.

5-(2,2-difluoropropyl)-3-fluoro-5,12-dimethylindolo[2,1-a]isoquinolin-6(5H)-one (5b). A yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 51.4 mg, 72 % yield. ¹H NMR (500 MHz, CDCl₃): δ 8.61 (d, *J* = 8.0 Hz, 1H), 8.03 (dd, *J* = 8.8, 6.0 Hz, 1H), 7.59 (d, *J* = 7.0 Hz, 1H), 7.42 – 7.35 (m, 2H), 7.17 – 7.11 (m, 2H), 3.28 – 3.18 (m, 1H), 2.63 (s, 3H), 2.62 – 2.55 (m, 1H), 1.69 (s, 3H), 1.38 (t, *J* = 19.0 Hz, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 171.2, 161.8 (d, *J* = 248.4 Hz), 139.8 (d, *J* = 6.9 Hz), 134.2, 132.4, 128.9, 126.9 (d, *J* = 8.3 Hz), 125.7, 124.3, 122.7 (t, *J* = 240.6 Hz), 122.4 (d, *J* = 2.5 Hz), 118.3, 116.7, 114.9 (d, *J* = 21.8 Hz), 114.1, 113.9, 48.1 (t, *J* = 24.1 Hz), 45.1, 31.2, 24.6 (t, *J* = 27.4 Hz), 11.4. ¹⁹F NMR (471 MHz, CDCl₃): δ -84.17 – -84.88 (m, 1F), -86.70 – -87.41 (m, 1F), -112.80 – -112.85 (m, 1F). HRMS (ESI-TOF) *m/z*: Calcd for C₂₁H₁₈F₃NO (M+H)⁺ 358.1413; Found 358.1415.

3-chloro-5-(2,2-difluoropropyl)-5,10,12-trimethylindolo[2,1-a]isoquinolin-6(5H)-one (5c). A yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 56.8 mg, 76 % yield. ¹H NMR (400 MHz, CDCl₃): δ 8.62 – 8.59 (m, 1H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.61 – 7.58 (m, 1H), 7.43 (d, *J* = 1.6 Hz, 1H), 7.41 – 7.35 (m, 3H), 3.28 – 3.16 (m, 1H), 2.63 (s, 3H), 2.67 – 2.55 (m, 1H), 1.69 (s, 3H), 1.38 (t, *J* = 18.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.2, 138.9, 134.2, 133.1,

132.3, 128.6, 127.6, 127.4, 126.2, 125.9, 124.5, 124.4, 122.8 (t, $J = 240.4$ Hz), 118.4, 116.7, 114.9, 48.0 (t, $J = 23.9$ Hz), 44.9, 31.2, 24.7 (t, $J = 27.3$ Hz), 11.5. ^{19}F NMR (471 MHz, CDCl_3): δ -84.35 – -85.06 (m, 1F), -86.79 – -87.49 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{21}\text{H}_{18}\text{ClF}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 374.1118; Found 374.1120.

*3-bromo-5-(2,2-difluoropropyl)-5,12-dimethylindolo[2,1-*a*]isoquinolin-6(5H)-one (5d)*. A yellowish liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 57.7 mg, 69% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.60 (d, $J = 7.5$ Hz, 1H), 7.90 (d, $J = 8.5$ Hz, 1H), 7.60 – 7.58 (m, 2H), 7.52 (dd, $J = 8.5$, 2.0 Hz, 1H), 7.43 – 7.35 (m, 2H), 3.27 – 3.17 (m, 1H), 2.63 (s, 3H), 2.65 – 2.56 (m, 1H), 1.68 (s, 3H), 1.38 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.1, 139.2, 134.3, 132.3, 130.5, 130.3, 128.7, 126.4, 126.0, 124.9, 124.4, 122.7 (t, $J = 240.5$ Hz), 121.2, 118.5, 116.8, 115.1, 48.1 (t, $J = 23.9$ Hz), 44.9, 31.2, 24.7 (t, $J = 27.3$ Hz), 11.5. ^{19}F NMR (471 MHz, CDCl_3): δ -84.40 – -85.07 (m, 1F), -86.79 – -87.47 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{21}\text{H}_{18}\text{BrF}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 420.0594; Found 420.0598.

*3-chloro-5-(2,2-difluoropropyl)-5,10,12-trimethylindolo[2,1-*a*]isoquinolin-6(5H)-one (5e)*. A yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 56.6 mg, 73% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.34 (d, $J = 8.5$ Hz, 1H), 7.84 (d, $J = 8.5$ Hz, 1H), 7.30 (s, 1H), 7.25 (d, $J = 9.0$ Hz, 1H), 7.15 (s, 1H), 7.11 (d, $J = 8.0$ Hz, 1H), 3.14 – 3.04 (m, 1H), 2.50 (s, 3H), 2.52 – 2.43 (m, 1H), 2.38 (s, 3H), 1.56 (s, 3H), 1.25 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 170.9, 139.0, 134.1, 133.0, 132.5, 132.5, 128.8, 127.6, 127.4, 127.2, 126.1, 124.6, 122.7 (t, $J = 240.4$ Hz), 118.5, 116.4, 114.7, 48.1 (t, $J = 24.0$ Hz), 44.9, 31.2, 24.6 (t, $J = 27.4$ Hz), 21.6, 11.5. ^{19}F NMR (471 MHz, CDCl_3): δ -84.19 – -84.90 (m, 1F), -86.72 – -87.42 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{22}\text{H}_{20}\text{ClF}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 388.1274; Found 388.1275.

*5-(2,2-difluoropropyl)-12-ethyl-5-methylindolo[2,1-*a*]isoquinolin-6(5H)-one (5f)*. A yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 52.9 mg, 75% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.64 (d, $J = 7.5$ Hz, 1H), 8.00 (d, $J = 8.0$ Hz, 1H), 7.61 (d, $J = 7.0$ Hz, 1H), 7.47 (d, $J = 7.5$ Hz, 1H), 7.44 – 7.35 (m, 4H), 3.26 – 3.13 (m, 3H), 2.70 – 2.61 (m, 1H), 1.70 (s, 3H), 1.42 (t, $J = 7.5$ Hz, 3H), 1.31 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 172.0, 137.1, 134.5, 131.8, 128.8, 127.5, 127.4, 127.3, 125.7, 124.7, 124.3, 122.9 (t, $J = 240.2$ Hz), 121.1, 118.2, 116.9, 48.1 (t, $J = 24.3$ Hz), 44.9, 31.3, 24.5 (t, $J = 27.4$ Hz), 18.6, 13.3. ^{19}F NMR (471 MHz, CDCl_3): δ -84.21 – -84.92 (m, 1F), -85.41 – -86.12 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{22}\text{H}_{21}\text{F}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 354.1664; Found 354.1667.

*5-(2,2-difluoropropyl)-12-ethyl-5,10-dimethylindolo[2,1-*a*]isoquinolin-6(5H)-one (5g)*. A yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 47.7 mg, 65% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.50 (d, $J = 8.5$ Hz, 1H), 7.98 (d, $J = 8.0$ Hz, 1H), 7.46 (d, $J = 7.5$ Hz, 1H), 7.45 – 7.35 (m, 3H), 7.22 (d, $J = 8.0$ Hz, 1H), 3.25 – 3.16 (m, 1H), 3.13 (q, $J = 7.5$ Hz, 2H), 2.69 – 2.60 (m, 1H), 2.51 (s, 3H), 1.69 (s, 3H), 1.41 (t, $J = 7.5$ Hz, 3H), 1.30 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.7, 137.0, 133.9, 132.6, 131.9, 128.9, 127.4, 127.3, 127.0, 125.8, 124.6, 122.9 (t, $J = 240.2$ Hz), 121.0, 118.2, 116.6, 48.1 (t, $J = 24.4$ Hz), 44.8, 31.2, 24.4 (t, $J = 27.4$ Hz), 21.6, 18.6, 13.3. ^{19}F NMR (471 MHz, CDCl_3): δ -84.10 – -84.77 (m, 1F), -85.39 – -86.06 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{23}\text{H}_{23}\text{F}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 368.1820; Found 368.1824.

*5-(2,2-difluoropropyl)-12-ethyl-10-fluoro-5-methylindolo[2,1-*a*]isoquinolin-6(5H)-one (5h)*. A yellow liquid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 51.9 mg, 70% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.57 (dd, $J = 9.0$, 5.0 Hz, 1H), 7.98 (d, $J = 7.5$ Hz, 1H), 7.47 (d, $J = 7.5$ Hz, 1H), 7.44 – 7.37 (m, 2H), 7.23 (dd, $J = 9.0$, 2.5 Hz, 1H), 7.09 (td, $J = 9.0$, 2.5 Hz, 1H), 3.24 – 3.15 (m, 1H), 3.12 – 3.07 (m, 2H), 2.69 – 2.60 (m, 1H), 1.69 (s, 3H), 1.40 (t, $J = 7.5$ Hz, 3H), 1.31 (t, $J = 19.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.8, 160.4 (d, $J = 241.1$ Hz), 137.3, 133.2 (d, $J = 9.4$ Hz), 130.7, 130.4, 127.65 (d, $J = 41.6$ Hz), 127.3, 125.4, 124.8, 122.8 (d, $J = 240.4$ Hz), 120.6 (d, $J = 4.1$ Hz), 118.0 (d, $J = 9.0$ Hz), 113.1 (d, $J = 24.6$ Hz), 104.0 (d, $J = 24.0$ Hz), 48.3 (t, $J = 24.2$ Hz), 44.8, 31.2, 24.6 (t, $J = 27.4$ Hz), 18.7, 13.2. ^{19}F NMR (471 MHz, CDCl_3): δ -84.78 – -85.42 (m, 1F), -85.86 – -86.52 (m, 1F), -118.11 – -118.16 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{22}\text{H}_{20}\text{F}_3\text{NO}$ ($\text{M}+\text{H}$) $^+$ 372.1570; Found 372.1575.

*3-chloro-5-(2-cyclopropyl-2,2-difluoroethyl)-5,12-dimethylindolo[2,1-*a*]isoquinolin-6(5H)-one (5i)*. A yellow solid after purification by flash column chromatography (petroleum ether/ethyl acetate = 20/1), 50.4 mg, 63% yield. ^1H NMR (500 MHz, CDCl_3): δ 8.61 (d, $J = 7.5$ Hz, 1H), 7.97 (d, $J = 8.5$ Hz,

1H), 7.59 (d, $J = 8.0$ Hz, 1H), 7.44 (s, 1H), 7.42 – 7.36 (m, 3H), 3.40 – 3.30 (m, 1H), 2.76 – 2.67 (m, 1H), 2.63 (s, 3H), 1.69 (s, 3H), 1.02 – 0.95 (m, 1H), 0.44 – 0.23 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 171.2, 139.2, 134.3, 133.1, 132.3, 128.8, 127.5, 126.1, 125.9, 124.4, 124.3, 122.4 (t, $J = 242.3$ Hz), 118.4, 116.8, 114.7, 47.7 (t, $J = 25.9$ Hz), 45.0, 31.7, 16.6 (t, $J = 28.9$ Hz), 11.5, 1.25 (dt, $J = 6.3, 3.1$ Hz). ^{19}F NMR (471 MHz, CDCl_3): δ -94.49 – -95.10 (m, 1F), -99.95 – -100.56 (m, 1F). HRMS (ESI-TOF) m/z : Calcd for $\text{C}_{23}\text{H}_{20}\text{ClF}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 400.1274; Found 400.1279.

4. Conclusions

In summary, a novel electrochemical tandem cyclization/difluoroethylation reaction of 2-arylbenzimidazoles/2-arylindoles was reported by our group. Various CF_2Me -substituted benzimidazo[2,1-*a*]isoquinolin-6(5*H*)-ones and indolo[2,1-*a*]isoquinolin-6(5*H*) ones could be readily synthesized with good to high yield. Additionally, it also offered a convenient protocol for the preparation of cyclopropyldifluoromethylated indolo[2,1-*a*]isoquinolin-6(5*H*) ones. Further investigation to construct other useful substituted heterocycles by electrochemical oxidative difluoroethylation is currently underway in our laboratory as well.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Figure S1: HRMS analysis of adduct products; Figure S2: Cyclic voltammograms of substrates; Figure S3: Structure of product **3m**; Figure S4: Structure of product **5i**; Tables S1 and S2: crystal and structure refinement data for **3m** and **5i**; ^1H NMR, ^{19}F NMR and ^{13}C NMR of compounds **3a–v** and **5a–i**.

Author Contributions: Conceptualization, Y.T.; methodology, D.G. and Y.T.; investigation, Y.T., L.Z., D.G., S.Y. and N.Z.; writing—original draft preparation, Y.T.; writing—review and editing, Y.T. and Z.L.; supervision, W.F.; funding acquisition, Y.T. and Z.L. All authors have read and agreed to the published version of the manuscript.

Funding: This project is supported by the National Natural Science Foundation of China (22302088 and 21702044), the Natural Science Foundation of Hebei Province (B2022201059), the Key Scientific Research Project of Higher Education of Henan Province (24B150022) and the Key Laboratory of Photochemical Conversion and Optoelectronic Materials, TIPC, CAS (PCOM202304).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data underlying this study are available in the published article and its Supporting Information. Deposition Numbers 2303467 (for **3m**) and 2307007 (for **5i**) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe “<http://www.ccdc.cam.ac.uk/structures>”.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Kirsch, P. *Modern Fluoroorganic Chemistry: Synthesis Reactivity, Applications*; Wiley-VCH: Weinheim, 2004.
2. Szpera, R.; Moseley, D. F. J.; Smith, L. B.; Sterling, A. J.; Gouverneur, V. The fluorination of C–H bonds: developments and perspectives. *Angew. Chem., Int. Ed.* **2019**, *58*, 14824–14848.
3. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. *Chem. Soc. Rev.* **2008**, *37*, 320–330.
4. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition. *Science* **2007**, *317*, 1881–1886.
5. Hu, X.; Tao, M.; Gong, K.; Feng, Q.; Hu, X.; Li, Y.; Sun, S.; Liang, D. Electrochemical or Photoelectrochemical Alkenylpolyfluoroalkylation of 3-Aza-1,5-dienes: Regioselective Entry to Polyfluoroalkylated 4-Pyrrolin-2-ones. *J. Org. Chem.* **2023**, *88*, 12935–12948.
6. Hiyama, T. *Organofluorine Compounds: Chemistry and Applications*; Springer: 2000.
7. O’Hagan, D.; Wang, Y.; Skibinski, M.; Slawin, A. M. Z. Influence of the difluoromethylene group (CF_2) on the conformation and properties of selected organic compounds. *Pure Appl. Chem.* **2012**, *84*, 1587–1595.
8. Zafrani, Y.; Yeffet, D.; Sod-Moriah, G.; Berliner, A.; Amir, D.; Marciano, D.; Gershonov, E.; Saphier, S. J. Difluoromethyl bioisostere: examining the “lipophilic hydrogen bond donor” concept. *J. Med. Chem.* **2017**, *60*, 797–804.
9. Meanwell, N. A. Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. *J. Med. Chem.* **2018**, *61*, 5822–5880.

10. Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackelford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Jiménez-Díaz, M. B.; Gamon, F.-J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential. *J. Med. Chem.* **2011**, *54*, 5540–5561.
11. Anderson, M. O.; Zhang, J.; Liu, Y.; Yao, C.; Phuan, P.-W.; Verkman, A. S. Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B. *J. Med. Chem.* **2012**, *55*, 5942–5950.
12. Zhou, Q.; Ruffoni, A.; Gianatassio, R.; Fujiwara, Y.; Sella, E.; Shabat, D.; Baran, P. S. Direct synthesis of fluorinated heteroarylether bioisosteres. *Angew. Chem. Int. Ed.* **2013**, *52*, 3949–3952.
13. Rong, J.; Deng, L.; Tan, P.; Ni, C.; Gu, Y.; Hu, J. Radical Fluoroalkylation of Isocyanides with Fluorinated Sulfones by Visible-Light Photoredox Catalysis. *Angew. Chem. Int. Ed.* **2016**, *55*, 2743–2747.
14. Zhou, N.; Liu, R.; Zhang, C.; Wang, K.; Feng, J.; Zhao, X.; Lu, K. Photoinduced Three-Component Difluoroalkylation of Quinoxalinones with Alkenes via Difluoroiodane(III) Reagents. *Org. Lett.* **2022**, *24*, 3576–3581.
15. Guo, C.; Han, X.; Feng, Y.; Liu, Z.; Li, Y.; Liu, H.; Zhang, L.; Dong, Y.; Li, X. Straightforward Synthesis of Alkyl Fluorides via Visible-Light Induced Hydromono- and Difluoroalkylations of Alkenes with α -Fluoro Carboxylic Acids. *J. Org. Chem.* **2022**, *87*, 9232–9241.
16. Gutiérrez-Bonet, A.; Liu, W. Synthesis of alkyl fluorides and fluorinated unnatural amino acids via photochemical decarboxylation of α -fluorinated carboxylic acids. *Org. Lett.* **2023**, *25*, 483–487.
17. Sperry, J. B.; Wright, D. L. The application of cathodic reductions and anodic oxidations in the synthesis of complex molecules. *Chem. Soc. Rev.* **2006**, *35*, 605–621.
18. Jutand, A. Contribution of electrochemistry to organometallic catalysis. *Chem. Rev.* **2008**, *108*, 2300–2347.
19. Feng, R.; Smith, J. A.; Moeller, K. D. Anodic cyclization reactions and the mechanistic strategies that enable optimization. *Acc. Chem. Res.* **2017**, *50*, 2346–2352.
20. Yan, M.; Kawamata, Y.; Baran, P. S. Synthetic organic electrochemical methods since 2000: on the verge of a renaissance. *Chem. Rev.* **2017**, *117*, 13230–13319.
21. Jiang, Y.; Xu, K.; Zeng, C.-C. Use of electrochemistry in the synthesis of heterocyclic structures. *Chem. Rev.* **2018**, *118*, 4485–4540.
22. Waldvogel, S. R.; Lips, S.; Selt, M.; Riehl, B.; Kampf, C. J. Electrochemical Arylation Reaction. *Chem. Rev.* **2018**, *118*, 6706–6765.
23. Chen, D.; Yang, X.; Wang, D.; Li, Y.; Shi, L.; Liang, D.-Q. Electrophotocatalytic tri- or difluoromethylative cyclization of alkenes. *Org. Chem. Front.* **2023**, *10*, 2482–2490.
24. Zhou, X.; Ni, C.; Deng, L.; Hu, J. Electrochemical reduction of fluoroalkyl sulfones for radical fluoroalkylation of alkenes. *Chem. Commun.* **2021**, *57*, 8750–8753.
25. Tian, Y.; Zheng, L.; Wang, Z.; Li, Z.-J.; Fu, W. Metal-Free Electrochemical Oxidative Difluoroethylation/Cyclization of Olefinic Amides To Construct Difluoroethylated Azaheterocycles. *J. Org. Chem.* **2023**, *88*, 1875–1883.
26. Tian, Y.; Zheng, L.; Yang, Y.; Liu, J.; Jing, Z.; Li, Z.-J.; Fu, W. Electrochemically Promoted Oxydifluoroethylation of Alkenes for the Synthesis of Difluoroethylated Benzoxazines and Lactones. *Adv. Synth. Catal.* **2023**, *365*, 1901–1906.
27. Polossek, T.; Ambros, R.; Von Angerer, S.; Brandl, G.; Mannschreck, A.; VonAngerer, E. 6-Alkyl-12-Formylindolo[2,1-a]isoquinolines. Syntheses, Estrogen Receptor Binding Affinities, and Stereospecific Cytostatic Activity. *J. Med. Chem.* **1992**, *35*, 3537–3547.
28. Goldbrunner, M.; Loidl, G.; Polossek, T.; Mannschreck, A.; von Angerer, E. Inhibition of Tubulin Polymerization by 5,6-Dihydroindolo[2,1-a]isoquinoline Derivatives. *J. Med. Chem.* **1997**, *40*, 3524–3533.
29. Faust, R.; Garratt, P. J.; Jones, R.; Yeh, L.-K.; Tsotinis, A.; Panoussopoulou, M.; Calogeropoulou, T.; Teh, M.-T.; Sugden, D. Mapping the Melatonin Receptor. 6. Melatonin Agonists and Antagonists Derived from 6H-Isoindolo[2,1-a]indoles, 5,6-Dihydroindolo[2,1-a]isoquinolines, and 6,7-Dihydro-5H-benzo[c]-azepino[2,1-a]indoles. *J. Med. Chem.* **2000**, *43*, 1050–1061.
30. Kraus, G. A.; Gupta, V.; Kohut, M.; Singh, N. A Direct Synthesis of 5,6-Dihydroindolo[2,1-a]isoquinolines that Exhibit Immunosuppressive Activity. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5539–5542.
31. Taublaender, M. J.; Glöckhofer, F.; Marchetti-Deschmann, M.; Unterlass, M. M. Green and Rapid Hydrothermal Crystallization and Synthesis of Fully Conjugated Aromatic Compounds. *Angew. Chem., Int. Ed.* **2018**, *57*, 12270–12274.
32. Zhang, M.; Tang, Z.; Fu, W.; Wang, W.; Tan, R.; Yin, D. An Ionic Liquid-Functionalized Amphiphilic Janus Material as a Pickering Interfacial Catalyst for Asymmetric Sulfoxidation in Water. *Chem. Commun.* **2019**, *55*, 592–595.
33. Sun, K.; Li, S. J.; Chen, X. L.; Liu, Y.; Huang, X. Q.; Wei, D. H.; Qu, L. B.; Zhao, Y. F.; Yu, B. Silver-Catalyzed Decarboxylative Radical Cascade Cyclization toward Benzimidazo[2,1-a]isoquinolin-6(5H)-ones. *Chem. Commun.* **2019**, *55*, 2861–2864.

34. Pan, C.; Yuan, C.; Yu, J.-T. Molecular Oxygen-Mediated Radical Cyclization of Acrylamides with Boronic Acids. *Adv. Synth. Catal.*, **2021**, 363, 4889–4893.
35. Yuan, Y.; Zheng, Y.; Xu, B.; Liao, J.; Bu, F.; Wang, S.; Hu, J.-G.; Lei, A. Mn-Catalyzed Electrochemical Radical Cascade Cyclization toward the Synthesis of Benzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-one Derivatives. *ACS Catal.* **2020**, 10, 6676–6681.
36. Zhang, J. R.; Liu, H. Y.; Fan, T.; Chen, Y. Y.; Xu, Y. L. Synthesis of Indolo[2,1-a]isoquinolin-6(5H)-Ones Derivatives via Fe(OTf)₃-Promoted Tandem Selenylation/Cyclization of 2-Arylindoles. *Adv. Synth. Catal.* **2021**, 363, 497–504.
37. Luo, Y. N.; Tian, T.; Nishihara, Y.; Lv, L. Y.; Li, Z. P. Iron-Catalysed Radical Cyclization to Synthesize Germanium-Substituted Indolo[2,1-a]isoquinolin-6(5H)-ones and Indolin-2-ones. *Chem. Commun.* **2021**, 57, 9276–9279.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.